Literature DB >> 12049454

Chemotherapeutic approaches to schistosomes: current knowledge and outlook.

A Harder1.   

Abstract

The chemotherapy of schistosomiasis has improved greatly in the last few decades. There are three drugs available: metrifonate (active against Schistosoma haematobium), oxamniquine (active against Schistosoma mansoni) as narrow spectrum drugs and praziquantel, which is effective against all important adult schistosome species and their immature stages, as the drug of choice.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12049454     DOI： 10.1007/s00436-001-0588-x

Source DB:  PubMed          Journal:  Parasitol Res        ISSN： 0932-0113            Impact factor:   2.289


  28 in total

Review 1.  Schistosomiasis--a century searching for chemotherapeutic drugs.

Authors:  Gabriela Ribeiro-dos-Santos; Sergio Verjovski-Almeida; Luciana C C Leite
Journal:  Parasitol Res       Date:  2006-04-25       Impact factor: 2.289

2.  Parasitological evaluation of Ro 15-9268, a 9-acridanone-hydrazone derivative against Schistosoma mansoni in mice, and observations on changes in serum enzyme levels.

Authors:  Sayed Rawi; Osama Abdel-Ghaffar Youssef; Aisha Metwally; Mohamed Badawy; Mansour Al-Hazmi
Journal:  Parasitol Res       Date:  2013-11-22       Impact factor: 2.289

3.  Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies.

Authors:  F C Cardoso; R N A Pacífico; R A Mortara; S C Oliveira
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

Review 4.  New insight into praziquantel against various developmental stages of schistosomes.

Authors:  Wei Wu; Wei Wang; Yi-Xin Huang
Journal:  Parasitol Res       Date:  2011-10-08       Impact factor: 2.289

Review 5.  Susceptibility or resistance of praziquantel in human schistosomiasis: a review.

Authors:  Wei Wang; Li Wang; You-Sheng Liang
Journal:  Parasitol Res       Date:  2012-10-07       Impact factor: 2.289

Review 6.  The redox biology of schistosome parasites and applications for drug development.

Authors:  Hsin-Hung Huang; Coraline Rigouin; David L Williams
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

7.  Recombinant Sj16 from Schistosoma japonicum contains a functional N-terminal nuclear localization signal necessary for nuclear translocation in dendritic cells and interleukin-10 production.

Authors:  Xi Sun; Fan Yang; Jia Shen; Zhen Liu; Jinyi Liang; Huanqin Zheng; Mingchiu Fung; Zhongdao Wu
Journal:  Parasitol Res       Date:  2016-09-17       Impact factor: 2.289

8.  Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.

Authors:  Maha-Hamadien Abdulla; Debbie S Ruelas; Brian Wolff; June Snedecor; Kee-Chong Lim; Fengyun Xu; Adam R Renslo; Janice Williams; James H McKerrow; Conor R Caffrey
Journal:  PLoS Negl Trop Dis       Date:  2009-07-14

9.  DNA vaccination by electroporation and boosting with recombinant proteins enhances the efficacy of DNA vaccines for Schistosomiasis japonica.

Authors:  Yang Dai; Yinchang Zhu; Donald A Harn; Xiaoting Wang; Jianxia Tang; Song Zhao; Fei Lu; Xiaohong Guan
Journal:  Clin Vaccine Immunol       Date:  2009-10-07

10.  Schistosoma mansoni Stomatin like protein-2 is located in the tegument and induces partial protection against challenge infection.

Authors:  Leonardo P Farias; Fernanda C Cardoso; Patricia A Miyasato; Bogar O Montoya; Cibele A Tararam; Henrique K Roffato; Toshie Kawano; Andrea Gazzinelli; Rodrigo Correa-Oliveira; Patricia S Coulson; R Alan Wilson; Sérgio C Oliveira; Luciana C C Leite
Journal:  PLoS Negl Trop Dis       Date:  2010-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.